Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay

Archives of Toxicology

Volumn 91, Issue 1, 2017, Pages 365-391

  Colaianna, Marilena ^a   Ilmjärv, Sten ^a   Peterson, Hedi ^b   Kern, Ilse ^c   Julien, Stephanie ^a   Baquié, Mathurin ^d   Pallocca, Giorgia ^e   Bosgra, Sieto ^f,i   Sachinidis, Agapios ^g   Hengstler, Jan G ^h   Leist, Marcel ^e   Krause, Karl Heinz ^a,c  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b Quretec Ltd ^*  (Estonia)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d NEURIX SA   (Switzerland)

^e UNIVERSITY OF KONSTANZ   (Germany)

^f TNO   (Netherlands)

^g UNIVERSITY OF COLOGNE   (Germany)

^h TU DORTMUND UNIVERSITY   (Germany)

ⁱ BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

In vitro screening; Mouse embryonic stem cells; Neuroactivity; Neuronal differentiation; Neurotoxicity

Indexed keywords

4 CHLOROMERCURIBENZOIC ACID; ABIRATERONE; ALISKIREN; AMIODARONE; ARSENIC TRIOXIDE; BELINOSTAT; BETA INTERFERON; CHLORPROMAZINE; ELONGATION FACTOR 1ALPHA; ENTINOSTAT; ERYTHROPOIETIN; EXENDIN 4; GELDANAMYCIN; GRANULOCYTE COLONY STIMULATING FACTOR; MERCURY BROMIDE; MERCURY DERIVATIVE; METHYLMERCURY; NEU DIFFERENTIATION FACTOR; OXYTOCIN; PEPTIDE HORMONE; PHENYLMERCURIC ACETATE; PROTEIN TYROSINE KINASE INHIBITOR; RIVAROXABAN; SILDENAFIL; SITAGLIPTIN; SULFADIAZINE; TELAPREVIR; TERIFLUNOMIDE; THIOMERSAL; UNCLASSIFIED DRUG; VALPROIC ACID; BIOLOGICAL MARKER; ELONGATION FACTOR 1; NEUROTOXIN; NEW DRUG; PHOTOPROTEIN; POLLUTANT; TUBA1A PROTEIN, MOUSE; TUBULIN;

ANIMAL CELL; ARTICLE; ASSAY; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DUAL LUMINESCENCE REPORTER ASSAY; EMBRYO; LUMINESCENCE; MOUSE; MOUSE EMBRYONIC STEM CELL; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL COMMUNICATION; CELL LINE; CELL SURVIVAL; COCULTURE; CYTOLOGY; DRUG EFFECTS; ENVIRONMENTAL MONITORING; GENETICS; METABOLISM; PLURIPOTENT STEM CELL; POLLUTANT; PRECLINICAL STUDY; PROMOTER REGION; REPORTER GENE; STROMA CELL; TOXICITY; VALIDATION STUDY;

ANIMALS; BIOMARKERS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; GENES, REPORTER; LUMINESCENT PROTEINS; MICE; MOUSE EMBRYONIC STEM CELLS; NEURONS; NEUROTOXINS; PEPTIDE ELONGATION FACTOR 1; PLURIPOTENT STEM CELLS; PROMOTER REGIONS, GENETIC; STROMAL CELLS; TUBULIN;

EID: 84961659642     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-016-1690-2     Document Type: Article

References (141)

1. Abrams PJ, Emerson CR (2009) Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy 29(2):167–181. doi:10.1592/phco.29.2.167
2. Australian Therapeutic Goods Administration (2013) Australian Public Assessment Report for Teriflunomide.PM-2011-02772-3; http://www.tga.gov.au/pdf/auspar/auspar-teriflunomide-130521.pdf
3. Australian Therapeutic Goods Administration T (2014) Australian Public Assessment Report for Abiraterone Acetate. PM-2012-02706-3-4;https://www.tga.gov.au/word/auspar/ausparabiraterone-acetate-140122.docx
4. Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis 4(3):337–344. doi:10.3233/JPD-140364
5. Baker H, Lindsey J, Weisbroth S (1979) The laboratory rat: biology and diseases, vol 1. Academic Press, London
6. Bal-Price A, Crofton KM, Leist M et al (2015) International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes. Arch Toxicol 89(2):269–287. doi:10.1007/s00204-015-1464-2
7. Balmer NV, Weng MK, Zimmer B et al (2012) Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Hum Mol Genet 21(18):4104–4114. doi:10.1093/hmg/dds239
8. Barber BJ, Schultz TJ, Randlett DL (1990) Comparative analysis of protein content in rat mesenteric tissue, peritoneal fluid, and plasma. Am J Physiol 258(5 Pt 1):G714–G718
9. Bauer S, Hilger RA, Muhlenberg T et al (2014) Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 110(5):1155–1162. doi:10.1038/bjc.2013.826
10. Besser R, Kramer G, Thumler R, Bohl J, Gutmann L, Hopf HC (1987) Acute trimethyltin limbic-cerebellar syndrome. Neurology 37(6):945–950
11. Breier JM, Gassmann K, Kayser R et al (2010) Neural progenitor cells as models for high-throughput screens of developmental neurotoxicity: state of the science. Neurotoxicol Teratol 32(1):4–15. doi:10.1016/j.ntt.2009.06.005
12. Busher JT (1990) Serum albumin and globulin. In: Walker HK, Hall WD, Hurst JW (eds) Clinical methods: the history, physical, and laboratory examinations, 3rd edn. Butterworth Publishers, Boston, pp 497–499
13. Campbell UB, Walker AM, Gaffney M et al (2015) Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med 12(1):139–151. doi:10.1111/jsm.12726
14. Charness ME, Morady F, Scheinman MM (1984) Frequent neurologic toxicity associated with amiodarone therapy. Neurology 34(5):669–671
15. Cheng T, Grasse L, Shah J, Chandra J (2015) Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma. Drugs Today (Barcelona) 51(8):491–504. doi:10.1358/dot.2015.51.8.2362311
16. Clark CB, Rane MJ, El Mehdi D, Miller CJ, Sachleben LR Jr, Gozal E (2009) Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. Free Radic Biol Med 47(10):1440–1449. doi:10.1016/j.freeradbiomed.2009.08.012
17. Clarkson TW, Strain JJ (2003) Nutritional factors may modify the toxic action of methyl mercury in fish-eating populations. J Nutr 133(5 Suppl 1):1539S–1543S
18. Coecke S, Goldberg AM, Allen S et al (2007) Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environ Health Perspect 115(6):924–931. doi:10.1289/ehp.9427
19. Costa LG, Giordano G, Tagliaferri S, Caglieri A, Mutti A (2008) Polybrominated diphenyl ether (PBDE) flame retardants: environmental contamination, human body burden and potential adverse health effects. Acta Biomed 79(3):172–183
20. Crofton KM (1996) A structure-activity relationship for the neurotoxicity of triazole fungicides. Toxicol Lett 84(3):155–159
21. Darnerud PO (2008) Brominated flame retardants as possible endocrine disrupters. Int J Androl 31(2):152–160. doi:10.1111/j.1365-2605.2008.00869.x
22. Daugherty KK (2008) Aliskiren. Am J Health Syst Pharm 65(14):1323–1332. doi:10.2146/ajhp070529
23. Davidson PW, Myers GJ, Weiss B (2004) Mercury exposure and child development outcomes. Pediatrics 113(4 Suppl):1023–1029
24. DeJongh J, Verhaar HJ, Hermens JL (1997) A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 72(1):17–25
25. Deng C, Pan B, Engel M, Huang XF (2013) Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway. Psychopharmacology 226(2):201–215. doi:10.1007/s00213-013-3003-2
26. Dewland PM, Reader S, Berry P (2009) Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. BMC Clin Pharmacol 9:19. doi:10.1186/1472-6904-9-19
27. Dietrich DR, von Aulock S, Marquardt H et al (2013) Scientifically unfounded precaution drives European Commission’s recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. ALTEX 30(3):381–385
28. Dorea JG, Farina M, Rocha JB (2013) Toxicity of ethylmercury (and Thimerosal): a comparison with methylmercury. J Appl Toxicol 33(8):700–711. doi:10.1002/jat.2855
29. Ekino S, Susa M, Ninomiya T, Imamura K, Kitamura T (2007) Minamata disease revisited: an update on the acute and chronic manifestations of methyl mercury poisoning. J Neurol Sci 262(1–2):131–144. doi:10.1016/j.jns.2007.06.036
30. Eskenazi B, Chevrier J, Rauch SA et al (2013) In utero and childhood polybrominated diphenyl ether (PBDE) exposures and neurodevelopment in the CHAMACOS study. Environ Health Perspect 121(2):257–262. doi:10.1289/ehp.1205597
31. Farina M, Rocha JB, Aschner M (2011) Mechanisms of methylmercury-induced neurotoxicity: evidence from experimental studies. Life Sci 89(15–16):555–563. doi:10.1016/j.lfs.2011.05.019
32. Foss F, Advani R, Duvic M et al (2015) A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 168(6):811–819. doi:10.1111/bjh.13222
33. Frederiksen M, Vorkamp K, Thomsen M, Knudsen LE (2009) Human internal and external exposure to PBDEs–a review of levels and sources. Int J Hyg Environ Health 212(2):109–134. doi:10.1016/j.ijheh.2008.04.005
34. Fukuyo Y, Hunt CR, Horikoshi N (2010) Geldanamycin and its anti-cancer activities. Cancer Lett 290(1):24–35. doi:10.1016/j.canlet.2009.07.010
35. Furst P (2006) Dioxins, polychlorinated biphenyls and other organohalogen compounds in human milk. Levels, correlations, trends and exposure through breastfeeding. Mol Nutr Food Res 50(10):922–933. doi:10.1002/mnfr.200600008
36. Gascon M, Fort M, Martinez D et al (2012) Polybrominated diphenyl ethers (PBDEs) in breast milk and neuropsychological development in infants. Environ Health Perspect 120(12):1760–1765. doi:10.1289/ehp.1205266
37. Giordano G, Costa LG (2012) Developmental neurotoxicity: some old and new issues. ISRN Toxicol 2012:12. doi:10.5402/2012/814795
38. Gojo I, Jiemjit A, Trepel JB et al (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109(7):2781–2790. doi:10.1182/blood-2006-05-021873
39. Goldberg T, Berrios-Colon E (2013) Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer. Pharm Ther 38(1):23–26
40. Goshman LM (1985) Clinical toxicology of commercial products, 5th ed. By R. E. Gosselin, R. P. Smith, and H. C. Hodge. Williams and Wilkins, 428 East Preston Street, Baltimore, MD 21202. 1984. 1987 + ix pp. 26 × 17.5 cm. ISBN 0-683-03632-7. $95.00. J Pharm Sci 74(10):1139. doi:10.1002/jps.2600741037
41. Grandjean P, Herz KT (2011) Methylmercury and brain development: imprecision and underestimation of developmental neurotoxicity in humans. Mt Sinai J Med 78(1):107–118. doi:10.1002/msj.20228
42. Grandjean P, Herz KT (2015) Trace elements as paradigms of developmental neurotoxicants: Lead, methylmercury and arsenic. J Trace Elem Med Biol 31:130–134. doi:10.1016/j.jtemb.2014.07.023
43. Grandjean P, Landrigan PJ (2006) Developmental neurotoxicity of industrial chemicals. Lancet 368(9553):2167–2178. doi:10.1016/S0140-6736(06)69665-7
44. Greene HL, Graham EL, Werner JA et al (1983) Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 2(6):1114–1128
45. Gulden M, Seibert H (2003) In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro. Toxicology 189(3):211–222
46. Harada M (1995) Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. Crit Rev Toxicol 25(1):1–24. doi:10.3109/10408449509089885
47. Hartung T, Leist M (2008) Food for thought on the evolution of toxicology and the phasing out of animal testing. ALTEX 25(2):91–102
48. Henley DV, Korach KS (2010) Physiological effects and mechanisms of action of endocrine disrupting chemicals that alter estrogen signaling. Hormones (Athens) 9(3):191–205
49. http://www.epa.gov/epawaste/hazard/tsd/pcbs/pubs/effects.htm
50. http://www.fao.org/fileadmin/templates/agphome/documents/Pests_Pesticides/JMPR/Report10/Cyproconazole.pdf
51. http://www.who.int/vaccine_safety/committee/topics/thiomersal/statement_jul2006/en/
52. Hurley AM, Tadrous M, Miller ES (2010) Thimerosal-containing vaccines and autism: a review of recent epidemiologic studies. J Pediatr Pharmacol Ther 15(3):173–181
53. International Programme on Chemical Safety http://www.inchem.org/documents/pims/pharm/pim441.htm
54. Itoh K, Tezuka H, Sakoda H et al (1989) Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 17(2):145–153
55. Iversen P, Beck B, Chen Y, et al (2012) HTS assay validation. In: Sittampalam GS Coussens N, Nelson H, et al (eds) Assay Guidance Manual [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004, Bethesda, MD
56. Jacobson JL, Jacobson SW (2001) Postnatal exposure to PCBs and childhood development. Lancet 358(9293):1568–1569. doi:10.1016/S0140-6736(01)06669-7
57. Kadereit S, Zimmer B, van Thriel C, Hengstler JG, Leist M (2012) Compound selection for in vitro modeling of developmental neurotoxicity. Front Biosci 17:2442–2460
58. Kern I, Xu R, Julien S et al (2013) Embryonic stem cell-based screen for small molecules: cluster analysis reveals four response patterns in developing neural cells. Curr Med Chem 20(5):710–723
59. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–1818. doi:10.1016/S0140-6736(08)61758-4
60. Klaric M, Winkler J, Vojnits K et al (2013) Current status of human pluripotent stem cell based in vitro toxicity tests. Front Biosci 5:118–133
61. Kreyberg S, Torvik A, Bjorneboe A, Wiik-Larsen W, Jacobsen D (1992) Trimethyltin poisoning: report of a case with postmortem examination. Clin Neuropathol 11(5):256–259
62. Krug AK, Balmer NV, Matt F, Schonenberger F, Merhof D, Leist M (2013a) Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol 87(12):2215–2231. doi:10.1007/s00204-013-1072-y
63. Krug AK, Kolde R, Gaspar JA et al (2013b) Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol 87(1):123–143. doi:10.1007/s00204-012-0967-3
64. Kuegler PB, Zimmer B, Waldmann T et al (2010) Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing. ALTEX 27(1):17–42
65. Kummar S, Gutierrez M, Gardner ER et al (2007) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 13(18 Pt 1):5411–5417. doi:10.1158/1078-0432.CCR-07-0791
66. Kummar S, Gutierrez ME, Gardner ER et al (2010) Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46(2):340–347. doi:10.1016/j.ejca.2009.10.026
67. Laske C, Stellos K, Stransky E, Leyhe T, Gawaz M (2009) Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer’s disease. J Alzheimers Dis 17(1):115–123. doi:10.3233/JAD-2009-1017
68. Lawless MW, Norris S, O’Byrne KJ, Gray SG (2009) Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 13(5):826–852. doi:10.1111/j.1582-4934.2008.00571.x
69. Leist M, Hartung T (2013) Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol 87(4):563–567. doi:10.1007/s00204-013-1038-0
70. Leist M, Hartung T, Nicotera P (2008) The dawning of a new age of toxicology. ALTEX 25(2):103–114
71. Leist M, Hasiwa N, Rovida C et al (2014) Consensus report on the future of animal-free systemic toxicity testing. ALTEX 31(3):341–356. doi:10.14573/altex.1406091
72. Leist M, Ringwald A, Kolde R et al (2013) Test systems of developmental toxicity: state-of-the art and future perspectives. Arch Toxicol 87(12):2037–2042. doi:10.1007/s00204-013-1154-x
73. Linden R, Ziulkoski AL, Wingert M, Tonello P, Souto AA (2007) Simultaneous determination of omeprazole, hydroxyomeprazole and omeprazole sulphone in human plasma by isocratic HPLC-DAD: application to the phenotyping of CYP2C19 and CYP3A4 in brazilian volunteers. J Braz Chem Soc 18:733–740
74. Lindup WEI (1987) Plasma protein binding of drugs: some basic and clinical aspects. In: Bridges JW, Chasseaud LF, Gibson GG (eds) Progress in drug metabolism, vol 10. Taylor and Francis, London, pp 141–185
75. Lohren H, Blagojevic L, Fitkau R et al (2015) Toxicity of organic and inorganic mercury species in differentiated human neurons and human astrocytes. J Trace Elem Med Biol 32:200–208. doi:10.1016/j.jtemb.2015.06.008
76. Lu E, Wang BW, Alwan S et al (2014) A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs 28(2):89–94. doi:10.1007/s40263-013-0131-5
77. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ (2011) A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 36(8):1114–1126. doi:10.1016/j.psyneuen.2011.02.015
78. Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26(26):4244–4252. doi:10.1200/JCO.2007.15.0185
79. Messer A (2010) Mini-review: polybrominated diphenyl ether (PBDE) flame retardants as potential autism risk factors. Physiol Behav 100(3):245–249. doi:10.1016/j.physbeh.2010.01.011
80. Mlejnek P, Dolezel P (2014) N-acetylcysteine prevents the geldanamycin cytotoxicity by forming geldanamycin-N-acetylcysteine adduct. Chem Biol Interact 220:248–254. doi:10.1016/j.cbi.2014.06.025
81. Morris E, Green D, Graudins A (2009) Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. J Med Toxicol 5(1):27–31
82. Orr CF, Ahlskog JE (2009) Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 66(7):865–869. doi:10.1001/archneurol.2009.96
83. Ozkan H, Cetinkaya M, Koksal N, Yapici S (2011) Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med 24(3):521–524. doi:10.3109/14767058.2010.501120
84. Patejdl R, Markmann S, Benecke R, Wittstock M (2013) Severe acute motor neuropathy after treatment with triple tyrosine kinase inhibitor BIBF 1120 (Nintedanib). Clin Neurol Neurosurg 115(9):1851–1852. doi:10.1016/j.clineuro.2013.01.011
85. Patel S (2013) Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol 72(2):277–286. doi:10.1007/s00280-013-2135-8
86. Patterson DG Jr, Needham LL, Pirkle JL et al (1988) Correlation between serum and adipose tissue levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin in 50 persons from Missouri. Arch Environ Contam Toxicol 17(2):139–143
87. Pellacani C, Tagliaferri S, Caglieri A et al (2014) Synergistic interactions between PBDEs and PCBs in human neuroblastoma cells. Environ Toxicol 29(4):418–427. doi:10.1002/tox.21768
88. Perrin D, Martin T, Cambet Y, Fremaux C, Scheer A (2006) Overcoming the hurdle of fluorescent compounds in kinase screening: a case study. Assay Drug Dev Technol 4(2):185–196. doi:10.1089/adt.2006.4.185
89. Pichichero ME, Gentile A, Giglio N et al (2008) Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 121(2):e208–e214. doi:10.1542/peds.2006-3363
90. Pili R, Salumbides B, Zhao M et al (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106(1):77–84. doi:10.1038/bjc.2011.527
91. Pistollato F, Bremer-Hoffmann S, Healy L, Young L, Stacey G (2012) Standardization of pluripotent stem cell cultures for toxicity testing. Expert Opin Drug Metab Toxicol 8(2):239–257. doi:10.1517/17425255.2012.639763
92. Plosker GL (2011) Interferon-beta-1b: a review of its use in multiple sclerosis. CNS Drugs 25(1):67–88. doi:10.2165/11206430-000000000-00000
93. Poole RM (2014) Belinostat: first global approval. Drugs 74(13):1543–1554. doi:10.1007/s40265-014-0275-8
94. Preynat-Seauve O, Suter DM, Tirefort D et al (2009) Development of human nervous tissue upon differentiation of embryonic stem cells in three-dimensional culture. Stem Cells 27(3):509–520. doi:10.1634/stemcells.2008-0600
95. Rasmussen TA, Tolstrup M, Moller HJ et al (2015) Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect Dis 2(1):ofv037. doi:10.1093/ofid/ofv037
96. Reboli AC, Mandler HD (1992) Encephalopathy and psychoses associated with sulfadiazine in two patients with AIDS and CNS toxoplasmosis. Clin Infect Dis 15(3):556–557
97. Reeves R, Thiruchelvam M, Richfield EK, Cory-Slechta DA (2004) The effect of developmental exposure to the fungicide triadimefon on behavioral sensitization to triadimefon during adulthood. Toxicol Appl Pharmacol 200(1):54–63. doi:10.1016/j.taap.2004.03.020
98. Rempel E, Hoelting L, Waldmann T et al (2015) A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol 89(9):1599–1618. doi:10.1007/s00204-015-1573-y
99. Richardson PG, Schlossman RL, Alsina M et al (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122(14):2331–2337. doi:10.1182/blood-2013-01-481325
100. Rinne ML, Lee EQ, Wen PY (2012) Central nervous system complications of cancer therapy. J Support Oncol 10(4):133–141. doi:10.1016/j.suponc.2011.11.002
101. Robinson JF, Theunissen PT, van Dartel DA, Pennings JL, Faustman EM, Piersma AH (2011) Comparison of MeHg-induced toxicogenomic responses across in vivo and in vitro models used in developmental toxicology. Reprod Toxicol 32(2):180–188. doi:10.1016/j.reprotox.2011.05.011
102. Rovida C, Longo F, Rabbit RR (2011) How are reproductive toxicity and developmental toxicity addressed in REACH dossiers? ALTEX 28(4):273–294
103. Roysommuti S, Carroll SL, Wyss JM (2003) Neuregulin-1beta modulates in vivo entorhinal-hippocampal synaptic transmission in adult rats. Neuroscience 121(3):779–785
104. Ruiz R, Raez LE, Rolfo C (2015) Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs 24(8):1101–1109. doi:10.1517/13543784.2015.1056779
105. Russo PA, Wiese MD, Smith MD, Ahern MJ, Barbara JA, Shanahan EM (2013) Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. Ann Pharmacother 47(3):e15. doi:10.1345/aph.1R542
106. Schneider A, Kuhn HG, Schabitz WR (2005) A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4(12):1753–1757
107. Silva-Pereira LC, Cardoso PC, Leite DS et al (2005) Cytotoxicity and genotoxicity of low doses of mercury chloride and methylmercury chloride on human lymphocytes in vitro. Braz J Med Biol Res 38(6):901–907
108. Smirnova L, Hogberg HT, Leist M, Hartung T (2014) Developmental neurotoxicity: challenges in the 21st century and in vitro opportunities. ALTEX 31(2):129–156. doi:10.14573/altex.1403271
109. Smith J, Whitehall J (2009) Sodium valproate and the fetus: a case study and review of the literature. Neonatal Netw 28(6):363–367. doi:10.1891/0730-0832.28.6.363
110. Stefanska B, MacEwan DJ (2015) Epigenetics and pharmacology. Br J Pharmacol 172(11):2701–2704. doi:10.1111/bph.13136
111. Stiegler NV, Krug AK, Matt F, Leist M (2011) Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures. Toxicol Sci 121(1):73–87. doi:10.1093/toxsci/kfr034
112. Subiros N, Del Barco DG, Coro-Antich RM (2012) Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord 5(3):161–173. doi:10.1177/1756285611434926
113. Sun HH, Saheb-Al-Zamani M, Yan Y, Hunter DA, Mackinnon SE, Johnson PJ (2012) Geldanamycin accelerated peripheral nerve regeneration in comparison to FK-506 in vivo. Neuroscience 223:114–123. doi:10.1016/j.neuroscience.2012.07.026
114. Suñol C, Rodríguez-Farré E (2012) In Vitro models for methylmercury neurotoxicity: effects on glutamatergic cerebellar granule neurons. In: Ceccatelli S, Aschner M (eds) Methylmercury and neurotoxicity. Current topics in neurotoxicity, vol 2. Springer, pp 259–270
115. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36(4):305–315. doi:10.1007/BF00689048
116. Suter DM, Cartier L, Bettiol E et al (2006) Rapid generation of stable transgenic embryonic stem cell lines using modular lentivectors. Stem Cells 24(3):615–623. doi:10.1634/stemcells.2005-0226
117. Suter DM, Preynat-Seauve O, Tirefort D, Feki A, Krause KH (2009) Phenazopyridine induces and synchronizes neuronal differentiation of embryonic stem cells. J Cell Mol Med 13(9B):3517–3527. doi:10.1111/j.1582-4934.2009.00660.x
118. Sweatman TW, Renwick AG, Burgess CD (1981) The pharmacokinetics of saccharin in man. Xenobiotica 11(8):531–540
119. Theunissen PT, Pennings JL, Robinson JF, Claessen SM, Kleinjans JC, Piersma AH (2011) Time-response evaluation by transcriptomics of methylmercury effects on neural differentiation of murine embryonic stem cells. Toxicol Sci 122(2):437–447. doi:10.1093/toxsci/kfr134
120. Thompson WW, Price C, Goodson B et al (2007) Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 357(13):1281–1292. doi:10.1056/NEJMoa071434
121. Tsuji R, Crofton KM (2012) Developmental neurotoxicity guideline study: issues with methodology, evaluation and regulation. Congenit Anom 52(3):122–128. doi:10.1111/j.1741-4520.2012.00374.x
122. US FDA (2011) Pharmacology review: abiraterone acetate (ZYTIGA). Center for drug evaluation and research, submission number 202379Orig1s000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000PharmR.pdf
123. US FDA (2012) Center for drug evaluation and research, Pharmacology Review Teriflunomide, submission number 202992Orig1s000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000PharmR.pdf
124. Vahidnia A, van der Voet GB, de Wolff FA (2007) Arsenic neurotoxicity: a review. Hum Exp Toxicol 26(10):823–832. doi:10.1177/0960327107084539
125. van Thriel C, Westerink RH, Beste C, Bale AS, Lein PJ, Leist M (2012) Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts. Neurotoxicology 33(4):911–924. doi:10.1016/j.neuro.2011.10.002
126. van Vliet E, Daneshian M, Beilmann M et al (2014) Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 31(4):479–493. doi:10.14573/altex.1405271
127. van Vliet E, Morath S, Eskes C et al (2008) A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotoxicology 29(1):1–12. doi:10.1016/j.neuro.2007.09.007
128. Varela MA, Roberts TC, Wood MJ (2013) Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy. Neurotherapeutics 10(4):621–631. doi:10.1007/s13311-013-0212-7
129. Verrotti A, Scaparrotta A, Cofini M, Chiarelli F, Tiboni GM (2014) Developmental neurotoxicity and anticonvulsant drugs: a possible link. Reprod Toxicol 48:72–80. doi:10.1016/j.reprotox.2014.04.005
130. Verwei M, van Burgsteden JA, Krul CA, van de Sandt JJ, Freidig AP (2006) Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. Toxicol Lett 165(1):79–87. doi:10.1016/j.toxlet.2006.01.017
131. Waldmann T, Rempel E, Balmer NV et al (2014) Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol 27(3):408–420. doi:10.1021/tx400402j
132. Wang C, Luan Z, Yang Y, Wang Z, Cui Y, Gu G (2011) Valproic acid induces apoptosis in differentiating hippocampal neurons by the release of tumor necrosis factor-alpha from activated astrocytes. Neurosci Lett 497(2):122–127. doi:10.1016/j.neulet.2011.04.044
133. Wei DG, Chiang V, Fyne E et al (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10(4):e1004071. doi:10.1371/journal.ppat.1004071
134. Welsch F (2005) The mechanism of ethylene glycol ether reproductive and developmental toxicity and evidence for adverse effects in humans. Toxicol Lett 156(1):13–28. doi:10.1016/j.toxlet.2003.08.010
135. Westermark T, Odsjö T, Johnels-Ambio AG (1975) Mercury content of bird feathers before and after Swedish ban on alkyl mercury in agriculture. Ambio 4:87–92
136. Willis MS, Lugo AM (2009) Amiodarone-induced neurotoxicity. Am J Health Syst Pharm 66(6):567–569. doi:10.2146/ajhp080196
137. Wu WC, Wu MH, Chang YC et al (2010) Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells. Exp Eye Res 91(2):211–219. doi:10.1016/j.exer.2010.05.005
138. Xu R, Feyeux M, Julien S et al (2014) Screening of bioactive peptides using an embryonic stem cell-based neurodifferentiation assay. AAPS J 16(3):400–412. doi:10.1208/s12248-014-9578-7
139. Zimmer B, Kuegler PB, Baudis B et al (2011) Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death Differ 18(3):383–395. doi:10.1038/cdd.2010.109
140. Zimmer B, Lee G, Balmer NV et al (2012) Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cells. Environ Health Perspect 120(8):1116–1122. doi:10.1289/ehp.1104489
141. Zimmer B, Pallocca G, Dreser N et al (2014) Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. Arch Toxicol 88(5):1109–1126. doi:10.1007/s00204-014-1231-9